<DOC>
	<DOC>NCT01491217</DOC>
	<brief_summary>The main objectives of this study are to determine the maximum tolerated dose (MTD) and recommend dose (RD) of Oraxol® in Phase I and to determine the objective response rate of Oraxol® in Phase II.</brief_summary>
	<brief_title>A Study of Oraxol® in Gastric Cancer Patients</brief_title>
	<detailed_description>Administration Schedule: 1 cycle of Oraxol® is 28 days and Oraxol® is administrated twice a week, total 6 times per cycle (day 1,2,8,9,15 and 16).</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1. Patients must histologically or cytologically be diagnosed to have an advanced solid cancer. (phaseI) 2. Advanced/metastatic/recurred gastric cancer(PhaseII) 3. ECOG performance status ≤ 2 4. Patients have proper bone marrow, kidney, liver function and patients do not have remarkable dysfunction of heart and lung: WBC≥4000/mm3; Platelet ≥100,000/mm3; Hemoglobin≥9.0g/dL; ANC≥ 1,500 /mm3; Creatinine ≤ 1.5mg/dL; AST/ALT/ALP ≤ 3 X the upper limit of normal; Total bilirubin ≤2.0mg/dL *AST/ALT/ALP ≤ 3 X the upper limit of normal but &lt;5 if liver or bone metastasis is present 1. Patients with blood tumor (ex, leukemia), uncontrolled infectious disease, neurologic disorders, metastasis to CNS or ileus (patients requiring nonoral administration of antibiotics to treat active bacterial infection are nor eligible, but patients can participate in the trial after complete eradication or control of the infection) 2. Patients who have received bone marrow transplant or are to receive bone marrow transplant. 3. Patients who had the medical history of atrial or ventricular arrhythmia or congestive heart failure or received medical treatment for myocardial infarction within 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Oraxol®</keyword>
	<keyword>oral paclitaxel</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>HM30181A</keyword>
	<keyword>MTD</keyword>
	<keyword>DLT</keyword>
	<keyword>RD</keyword>
</DOC>